Return to homepagePandemic Pact

Pneumonia & Pandemic Preparedness

Grant number: INV-033019

Grant search

Key facts

  • Disease

    Bacterial infection caused by Klebsiella pneumonia

  • Start & end year

    2021
    2025

  • Known Financial Commitments (USD)

    $844,427

  • Funder

    Gates Foundation

  • Principal Investigator

    N/A

  • Research Location

    Belgium

  • Lead Research Institution

    GlaxoSmithKline Biologicals

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

To characterize Klebsiella pneumoniae capsular (K) and sub-capsular (O) antigens among strains causing neonatal sepsis in low and middle-income countries

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

Development and Characterization of a Ten-Plex Assay to Measure <i>Klebsiella pneumoniae</i> Antigen-Specific IgG in Human Sera.

The characterization of Klebsiella pneumoniae associated with neonatal sepsis in low- and middle-income countries to inform vaccine design.

Development and Application of a High-Throughput Method for the Purification and Analysis of Surface Carbohydrates from Klebsiella pneumoniae.